West Virginia University

wvu.edu

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

153

Active

35

Phase 3

5

Total enrollment

10,510

Pipeline matrix

Showing 22 of 22 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Early Dual IV Antibiotic Therapy - MRSA1
Early Dual IV Antibiotic Therapy - MSSA1
Single Agent IV Antibiotic Therapy - MRSA1
Single Agent IV Antibiotic Therapy - MSSA1
Xylitol Gum1
Cooled Sodium Chloride1
Warmed Sodium Chloride1
Pioglitazone 15mg1
Pioglitazone 30 mg1
Leflunomide 10mg1
Leflunomide 20mg1
Decitabine1
Subcutaneous Blinatumomab1
Eravacycline1
Hydroxychloroquine sulfate1
Daratumumab1
Calaspargase pegol-mknl1
Cannabidiol (CBD) Oil 300mg1
Cannabidiol (CBD) Oil 150mg1
5% 5-fluorouracil (5-FU) powder1
5% 5-fluorouracil1
HIPEC1

Next readouts

  • 2025-12-31
  • 2026-03
  • 2026-12
  • 2026-12
  • 2027-01
  • 2027-06
  • 2027-07
  • 2027-07
  • 2027-10
  • 2027-12

Top conditions

  • Sleep Quality7
  • Breast Cancer5
  • Hypertension3
  • Glaucoma3
  • Obesity3
  • Glioblastoma3
  • Postpartum Disorder2
  • Lung Cancer2

Frequently asked questions about West Virginia University

How many clinical trials does West Virginia University have on ClinicalTrials.gov?
West Virginia University is listed as the lead sponsor on 153 clinical trials in ClinicalTrials.gov, 35 of which are currently active (recruiting, enrolling, or ongoing).
How many of West Virginia University's trials are in Phase 3?
5 of West Virginia University's trials are in Phase 3, spread across 22 active drug programs.
What therapeutic areas does West Virginia University focus on?
West Virginia University's most-studied conditions on ClinicalTrials.gov are Sleep Quality, Breast Cancer, Hypertension, Glaucoma, Obesity.
When are West Virginia University's next clinical trial readouts?
West Virginia University has 10 upcoming primary-completion readouts tracked here; the soonest is “2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML”, expected around 2025-12-31.